



**Written submission from  
Brain Tumor Foundation of Canada**

**Mémoire de  
Brain Tumor Foundation of Canada**

In the Matter of

À l'égard de

**Application to allow the production of  
lutetium-177(Lu-177) at the Bruce Nuclear  
Generating Station (NGS)**

---

**Demande de modification de permis visant à  
permettre la production de lutécium 177 à la  
centrale nucléaire de Bruce**

---

Public Hearing - Hearing in writing based on  
written submissions

Audience Publique - Audience fondée sur des  
mémoires

**June 2021**

**Juin 2021**



May 27, 2021

Tribunal Officer, Secretariat  
Canadian Nuclear Safety Commission  
280 Slater Street  
P.O. Box 1046, Station B  
Ottawa, Ontario K1P 5S9  
Email: [cnscc.interventions.ccsn@canada.ca](mailto:cnscc.interventions.ccsn@canada.ca)

**Re: Bruce Power Licence Amendment Application (June 25, 2021 Hearing in Writing)**

Dear President and Commission Members,

On behalf of Brain Tumour Foundation of Canada, we are pleased to support the licence amendment application made by Bruce Power Inc. regarding their Isotope Production System.

Brain Tumour Foundation of Canada is a proud partner with Bruce Power Inc. and can speak to the significant contribution they make to our health care community through the production of medical isotopes used in life-saving therapies for many different disease groups. The brain tumour population has very limited treatments available and Bruce Power Inc. plays an important role to patients worldwide through their production of Cobalt 60 and other medical isotopes. These isotopes are used in the production of Gamma Knife technology, a treatment used by radiation oncologists for brain tumour patients.

Once operational, the Isotope Production System will first be used to produce Lutetium-177 (Lu-177) which is currently used to treat neuroendocrine tumours and has additional applications for prostate and breast cancer treatments. Bruce Power's ability to contribute to the supply chain of Lu-177 and other medical isotopes is becoming increasingly important for Canadians and will open the door to large scale research and development opportunities critical for our brain tumour community.

Should you have any further questions regarding our support of this application, please do not hesitate to contact me directly at [smarshall@braintumour.ca](mailto:smarshall@braintumour.ca) or by phone at 519-642-7755 Ext 222.

Sincerely,

A handwritten signature in black ink that reads 'Susan Marshall'.

Susan Marshall, CEO  
Brain Tumour Foundation of Canada

519.642.7755 | 1.800.265.5106 | [www.braintumour.ca](http://www.braintumour.ca)

Brain Tumour Foundation of Canada | 205 Horton Street E, Suite 203 | London, ON N6B 4K1